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1. Introduction
Tolerance in human transplantation can be defined in two ways [1]. Clinical tolerance (also
referred to as clinical operational tolerance [2]) is the survival of a foreign organ or tissue
(allogeneic or xenogeneic) in a normal recipient in the absence of immunosuppression [1].
Immune tolerance is the absence of a detectable immune response against a functional organ
or tissue in the absence of immunosuppression [1].
Early evidence demonstrating that adult mice could be tolerant of skin grafts after the
induction of neonatal tolerance by the introduction of splenocytes intraperitoneally was shown
by Brent and Medawar, in 1953 [3]. The central role of the thymus in mediating cellular
immunity and graft rejection was established by JFAP Miller, who showed that nude mice
tolerated skin allografts because of a marked deficiency of lymphocytes [4]. Conversely, there
have been recent studies that show that spleen transplantation in pigs or dogs has a tolerogenic
effect on renal transplantation [5, 6]. On the basis of the promising results obtained in these
animal models, several tolerogenic protocols have been attempted in humans, but most have
failed to achieve robust and stable tolerance after renal transplantation. This is due to that the
transplantation immunobiology is very complex, because of the involvement of several
components such as antibodies, antigen presenting cells, helper and cytotoxic T cell subsets,
immune cell, surface molecules, signaling mechanisms and cytokines; which play a role in the
alloimmune response.
2. The alloimmune response
The allogeneic immune response has largely been attributed to the recognition of donor
antigens, presented in the context of human leukocyte antigen (HLA) molecules to T cells,
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which in turn direct a huge array of cellular and humoral responses, causing tissular damage
and graft rejection. This type of response is mediated by the adaptative branch of the immune
system [7].
The immune system can be divided in two components, the innate and adaptative immunity.
The innate immunity, refers to a nonspecific response that involves the recruitment of diverse
components of the immune system such as, macrophages, neutrophils, natural killer cells (NK
cells), cytokines, several cellular receptors, complement components, cytokines, Toll-like
receptors (TLRs), and antimicrobial peptides (AMP’s). The adaptative immunity, which
involves recognition of specific antigen, conferring both specificity and a memory effect [8].
Data suggest that initial allograft injury (such as ischemia) may initiate an innate immune
response (Figure 1A), thus contributing to acute and chronic allograft rejection. Furthermore,
this inflammatory response may initiate and expand the adaptive immune response to the
point where the different HLA antigens come into play for the first time [9]. Some immunol‐
ogist choose not to divide the alloimmune response in adaptative and innate branches;
nevertheless, they are closely related and dependent on each other.
The main and strongest responses to alloantigens are mediated by host T cells, which recognize
peptide antigens presented by antigen presenting cells (APCs) in the context of HLA. The
phenomenon by which the recipient immune system reacts with donor antigens that are
considered to be “non-self” is called allorecognition. Foreign or donor antigen presentation to
T cells may occur by either direct or indirect pathways [10] (Figure 2A).
2.1. Direct allorecogniton pathway
The direct allorecognition pathway involves recognition of intact donor HLA molecules on
the donor cells, usually APCs. This seems to contradict the classic self-HLA restriction property
of T cells, since the peptide being recognized is presented in a non-self HLA, and to date, two
models have been proposed to explain this discrepancy [11].
The “high determinant density” model proposes that the transplanted organ carries a variable
number of passenger APCs in the form of interstitial dendritic cells (DCs). Such APCs have a
high density of allo-HLA molecules and are capable of directly stimulating the recipient's T
cells. Given the very high ligand density, the affinity of alloreactive T cell receptors required
to generate an optimal alloimmune response can be significantly lower compared to that
required for self-HLA peptide complex [12].
In the “multiple binary complex” model, peptides derived from endogenous proteins that are
bound into the groove of donor HLA molecules play a role. These peptides are derived from
the same normal cellular proteins that are present even in the recipient. However, the differ‐
ences in the allo-HLA groove causes a different set of peptides to be presented from homolo‐
gous proteins. These peptides can be recognized by the recipient T cells. Therefore, even a
single HLA mismatch between the donor and the recipient would be able to stimulate a large
number of alloreactive T cells [13].
This pathway is thought to be the dominant pathway involved in the early alloimmune
response (acute graft rejection), as the relative number of T cells that proliferate on contact with
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allogeneic or donor cells is extraordinarily high compared with the number of clones that target
antigen presented by self-APCs [14].
Figure 1. The alloimmune response: (A) ischemia may initiate an innate immune response, (B) which contributes to
acute and chronic allograft rejection. The initial allograft injury, during reperfusion, is associated with generation of
DAMPs for maturation of donor-derived and recipient-derived dendritic cells, (C) which represents the bridge to the
development of an adaptive alloimmune response that results in rejection. Abbreviations: DAMPs, Damage-Associat‐
ed Molecular Patterns; NF- κβ, Nuclear Factor- κappa beta; DC, Dendritic Cell.
2.2. Indirect allorecognition pathway
In the indirect pathway, T cells recognize processed alloantigen presented as peptides by self-
APCs (host-APCs) [11]. The basic premise for indirect allorecognition as a mechanism involved
in allograft rejection is shedding of donor HLA molecules from the graft. These HLA molecules
are then taken up by recipient APCs and presented to CD4+ T cells. Interestingly, there is also
evidence that demonstrates that recipient DCs can acquire and process intact donor HLA
molecules from donor cell debris and stimulate CD8+ T cells by cross priming. Therefore, both
CD4+ and CD8+ T cells mediate indirect allorecognition [11]. The indirect pathway is postu‐
lated to play a dominant role in chronic allograft rejection [15].
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Figure 2. A). Allorecognition process. Two pathways lead to T-cell activation, the direct pathway and the indirect
pathway. The mechanisms of tolerance are: (B) Central tolerance in which T cells migrate from the bone marrow to
the thymus where they are educated, such that those recognizing self-antigens are deleted, and (C) Peripheral mecha‐
nisms of tolerance for self-reactive T cells including AICD, anergy, and suppression by Treg. (D) B-cell awaiting the prop‐
er stimulus of a T-cell to initiate the production of alloantibodies. Two possible scenarios ensure tolerance: deletion of
these self-reactive B cells and receptor editing, which is a process by which a new receptor with altered specificity is
generated through another sequence of B cell receptor gene rearrangements. Abbreviations: HLA, Human Leukocyte
Antigen; APC, Antigen Presenting Cells; TCR, T-cell Receptor; T, T-cell; T reg, regulatory T cells; B, B-cell; IL-2; Interleu‐
kin-2; AICD, Activation-Induced Cell Death.
2.3. Other allorecognition pathways
A third mode of allorecognition, which Lechler’s group has termed the “semi-direct” pathway,
has been recently proposed [16]. This model is based on the transfer of intact HLA molecules
between cells. DCs have been shown to acquire intact HLA class I and II molecules from
exosomes secreted by other DCs and to prime both naïve CD8+ and CD4+ T cells, thereby
inducing an alloimmune response [17,18].
Another mechanism of allorecognition involves NK cells. NK cells may recognize HLA
classical and non-classical type I molecules through interactions with cell surface receptors
called killer cell immunoglobulin-like receptors (KIR, formerly named killer inhibitory
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receptors) that recognize classical HLA class I molecules [19] and CD94/NKG2 receptors that
recognize non-classical HLA class I molecules. Currently, the role of NK cell-mediated
cytotoxicity in allograft rejection remains controversial, but recent data shows that NK cells
are potent alloreactive cells when fully activated with IL-15 and can mediate potent acute skin
rejection, at least in a murine model [20]. While reports continue to provide evidence support‐
ing a role for NK cells in promoting rejection, there are a growing number of studies that
illustrate an alternative role for NK cells in promoting allograft survival and tolerance [21].
2.4. Activation of T cells
Through their specific antigen receptors, T cells are capable of recognizing external antigens
and initiating immune responses. These reactions may be characterized predominantly by cell-
mediated reactions in which effector immune cells play a major role; or by humoral reactions
in which the stimulation of B cells (Figure 2D) may induce antibody responses. The T cells
orchestrate both the initiation and the propagation of immune responses, largely through the
secretion of protein mediators termed cytokines and chemokines. Moreover, recent findings
suggest that a novel subtype of T cells, named regulatory T cells, have an important role in
achieving allograft tolerance [22]. These facts make T cells important targets for immunosup‐
presive therapy and tolerance induction protocols.
T cells require two separate signals before activation occurs. The first signal is antigen specific
and is provided by the interaction of a T cell receptor (TCR) with a peptide antigen presented
within the antigen binding groove of HLA molecules on the surface of APCs (Figure 2A). These
are HLA class I molecules in the case of CD8+ T cells and class II molecules in the case of CD4+
T cells. The second, costimulatory, signal is provided by the interaction of T cell surface
molecules with their ligands on APCs, being the most important the B71-CD28 and CD40-
CD154 interactions. The first signal in the absence of the second signal may lead to T cell
inactivation, anergy, or failure of a Th1 (T helper cell-1) response with a switch to a Th2 (T
helper cell-2) response [23].
The Th1/Th2 response refers to the pattern of cytokines produced by T helper cells. Th1 cells
produce interleukin-12 (IL-12) and interferon gamma (IFN-gamma) inducing macrophage
activation leading to delayed-type hypersensitivity responses. The Th1 response has been
implicated in acute allograft rejection. Th2 cells produce IL-4, IL-5, IL-10, and IL-13, and
provide help for B cell function [24]. IL-4 is a growth factor for B cells and antibody production,
and also can directly inhibit T cell maturation along the Th1 pathway [25]. Such responses have
been associated with allograft tolerance, but are mainly implicated in clearing parasitic
infections and the presentation of allergic diseases.
Once the binding of CD4/CD8 co-receptors stabilizes the immunologic synapse between the
T cell and the APC, tyrosine-based activation motifs on the CD3 complex leads to the phos‐
phorylation of a series of intracellular proteins, resulting in the activation of a variety of
enzymes including calcineurin, and the activation of transcription factors, such as nuclear
factor of activated T cells (NFAT) and NF-κβ, permitting the transcription of different genes,
1 B7-1 (or CD80) and B7-2 (or CD86).
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including HLA class I and IL-2 [26]. There are other important events implicated in the
activation of T cells, including leukocyte migration and the interaction of chemokines with
their receptors.
3. Transplantation tolerance
The alloimmune response can be divided into central and peripheral tolerance, according to the
mechanisms that induce a tolerance state. These are related and not exclusive [27] (Figure 2).
3.1. Central tolerance
Central tolerance is the most important means by which T and B autoreactive lymphocytes are
eliminated in a process termed clonal deletion. T and B cells mature and are educated in the
thymus and the bone marrow, respectively (Figure 2B).
Immature T lineage cells emerge from hematopoietic progenitors in the bone marrow and enter
the thymus without expressing either the TCR or coreceptors. Since they lack CD4 and CD8
antigens, these cells are called double-negative (DN) cells or thymocytes. T cell selection begins
after DN cells have undergone a TCR-mediated rearrangement process and up-regulated both
CD4 and CD8 antigens, thus becoming double-positive (DP) cells [28]. From here, the thymo‐
cyte’s fate is determined by the nature of its interaction with self-peptides that are presented
on the self-HLA molecules of thymic stromal cells. This process is called “the affinity-avidity
model”. If a T cell reacts too strongly with self-antigens presented on bone marrow–derived
APCs, it is eliminated by apoptosis or negative selection in the thymus [29]. Thymocytes with
TCRs that interact with self HLA/peptides with lesser avidity, are positively selected and
evolve into mature T cells that express either the CD4 or CD8 receptor (single positive T cells).
The cells with very low avidity interactions fail to induce survival signals and die within the
thymus. At the end of the process, only 3% of the total number of CD4+CD8+ DP cells are
exported from the thymus, having developed into single positive CD4+ or CD8+ cells [30].
Currently,  it  is  not  completely understood how many peripheral  tissue-specific  antigens
are expressed and presented in the thymus to ensure central T-cell tolerance to antigens
that  will  be  encountered in  the  periphery eventually.  The expression of  peripheral  pro‐
teins in the thymus (such as insulin,  thyroglobulin,  and renal autoantigens) is  driven in
part by a gene called AIRE (autoimmune regulator). Mutations in the AIRE gene result in
a disease known as autoimmune polyglandular syndrome type I.  Interestingly, only cer‐
tain organs and systems are involved, and within these, only particular parts of the organ
tend to be affected, confirming that additional mechanisms must be involved to maintain
systemic tolerance [31].
B cells undergo a similar process, as they are tested for reactivity to self-antigens before they
enter the periphery. Immature B cells, developing in the bone marrow, test antigen through
their antigen receptor, a surface IgM called the B cell receptor (BCR). If signaling through the
BCR is sufficiently weak, immature B cells can be rendered permanently unresponsive or
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anergic. However, if immature B cells are strongly self-reactive, there are two possible
scenarios to ensure tolerance. The first is deletion of these self-reactive B cells. The second is
receptor editing, a process by which a new receptor with altered specificity is generated
through another sequence of B cell receptor gene rearrangements [32].
3.2. Peripheral tolerance
Besides the deletion process of autoreactive cells occurring during central tolerance, some T
or B cells with self-reactivity may escape from the thymus or bone marrow, making the loss
of self-tolerance easier. However, several mechanisms, collectively named peripheral toler‐
ance, can control or eliminate such cells. Peripheral tolerance involves deletion and apoptosis,
anergy, and regulation or suppression (Figure 2C).
3.2.1. Deletion and apoptosis
This mechanism is used to eliminate activated T cells specific for self-antigen. The programmed
cell death, or apoptosis, is also termed activation-induced cell death (AICD). This process is
mediated by the interaction of Fas (CD95) with its ligand (Fas-L or CD95L) on T cells, and can
occur in developing thymocytes as well as mature T cells [33]. IL-2 can activate the STAT 5 sig‐
naling pathway through the IL-2 receptor (IL-2R), which in turn potentiates the up-regulation
of Fas-L and the down-regulation of Bcl2 expression on T cells, thus promoting AICD. Con‐
versely, IL-15 acts as a growth and survival factor for T cells [34, 35]. Since augmented AICD can
induce tolerance through elimination of populations of reactive lymphocytes [36], certain tol‐
erogenic models which use IL-15 antagonists and IL-2 agonists during transplantation havere‐
sulted  in  donor-specific  tolerance  [37].  Further  research  on  this  topic  is  needed  before
considering this peripheral mechanism as a therapeutic approach.
3.2.2. Anergy
The hyporesponsiveness of T or B cells to further antigenic stimulation, also called anergy, is
a process that can result from antigenic stimulation in the absence of costimulation. In the case
of T cells, complete activation requires the presentation of peptide on the HLA molecule to the
TCR (first signal), and costimulatory signals, such as the B7-CD28 and CD40-CD154 interac‐
tions (second signal). The second signal is required to induce the multiple pathways that will
lead to the activation of IL-2 gene transcription, ultimately inducing T cell activation and
proliferation. However, it has been shown that IL-2 production and subsequent signaling
through its receptor, IL-2R, is necessary for T cells to escape anergy, since blocking IL-2/IL-2R
engagement even after stimulation through the TCR and CD28 still results in induction of T
cell anergy [38].
As with T cell activation, B cell activation requires two signals. In this context, naïve B cells
can be anergized if their surface immunoglobulins bind to self-antigens (first signal) in the
absence of the additional necessary T cell signals (second or costimulatory signal) [39].
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3.2.3. Regulation or suppression
A third mechanism of peripheral tolerance is regulation or suppression of immune responses to
self or foreign antigens. Perhaps, the regulatory T cells (Treg cells) are the most important and
well documented effectors of this mechanism to date. These cells control the type and magni‐
tude of the immune response to foreign antigen to ensure that the host remains undamaged.
Treg cells are also integral to maintaining a lack of response to self-antigens or tolerance [40].
There are two subsets of Treg cells.“Natural” Treg cells, are a thymus-derived population that
constitute about 10% of the CD4 population. Natural Treg cells express CD4, CD25, CTLA4,
and GITR on their surface [41], and express transcription factor Foxp3 intracellularly [42]. The
importance of Foxp3 as the orchestrator of the molecular programs involved in mediating Treg
function has been highlighted by diseases such as IPEX syndrome (immune dysfunction,
polyendocrinopathy, enteropathy and X-linked inheritance), in which a mutation in the Foxp3
gene has been described [43].
The other subset of Treg cells, commonly termed “adaptative” Treg cells, develops in the
periphery, in a thymic-independent manner, following antigen encounter under particular
circumstances, namely exposure to transforming growth factor-β (TGF-β). This leads to the
expression of Foxp3; the hallmark of Treg cells [44]. Data suggesting the role of these cells in
immunologic tolerance has been obtained from different studies in which patients with normal
graft function reportedly possess a smaller Treg population compared with patients having
chronic allograft rejection, suggesting that Treg cells may prevent damage and graft loss [45].
Other groups have shown that certain immunosuppressive protocols are more permissive than
others in generating these populations [46].
The mechanisms by which Treg cells exert their effects are not completely understood. There
have been two main mechanisms proposed. One mechanism requires cell contact between
CD4+CD25+ Treg and responder cells and interaction between CTLA-4 and GITR molecules
[47], while the other mechanism involves the induction of suppression or regulation by newly
generated suppressor T cells in a cytokine-dependent manner through IL-10 and/or TGF β [48,
49]. Although promising, there is still too much to learn, before using this subset of cells for
tolerance induction in renal transplantation.
In addition to Treg cells, there are other cell phenotypes with regulatory properties, such as
CD8+ T cells and certain NK populations [50]. CD8+ T cells with regulatory/suppressive
properties have been named “veto cells”. Such cells maintain peripheral tolerance by attacking
alloreactive T cells which are present in bone marrow with increased frequency, and may be
responsible in part for the reduction in graft versus host disease and the induction of chimerism
seen in some bone marrow transplant models [51].
4. Tolerogenic strategies in renal transplantation
Tolerance in renal  transplantation is  an exceptional  finding.  Approximately 100 cases of
tolerance  in  renal  transplantation  have  been  reported  to  date,  mainly  in  patients  who
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were not  compliant  with their  immunosuppressive regimens or  in individuals  who had
previously  received  a  bone  marrow  transplant  for  hematological  disorders  [52].  At  the
present time, in looking for tolerance in renal transplantation, physicians in clinical prac‐
tice  have  implemented  protocols  and  surgical  procedures  in  which  tolerance  was  the
planned objective before the transplant.
4.1. Strategies and protocols
Protocols in which tolerance in renal transplantation was the planned objective before the
transplant may be divided into three subgroups, namely molecule-based, cell-based, and total
lymphoid irradiation.
4.1.1. Molecule-based protocols
The molecule-based group includes all cases in which the induction of tolerance was attempted
through administration of presumed tolerogenic drugs. These tolerogenic drugs include
polyclonal antithymocyte globulin antibodies and anti-CD25 monoclonal antibodies. Anti-
CD25 monoclonal antibodies competitively inhibit IL-2R-dependent T cell activation, while
the polyclonal antithymocyte globulin antibodies are directed against lymphocyte antigens.
The goal of the induction treatment was the nonspecific removal of clones of immune cells
responsible for rejection before contact with foreign donor antigens occured. Once the donor
antigens were in place after implantation of the new kidney, repletion of immune cells occured,
favored by the homeostatic expansion triggered by leukocyte depletion. In addition, minimi‐
zation of maintenance immunosuppression was implemented to further reduce the anti donor
response with just enough treatment to prevent irreversible immune damage to the graft, but
not with such heavy treatment that the donor specific clonal exhaustion-deletion process was
precluded [53].
4.1.2. Cell-based protocols
In the cell-based group, patients received a donor-cell infusion of highly enriched CD34+
hematopoietic progenitor cells mixed with CD3+ T cells, [54] ie, patients received heavy
conditioning regimens in association with the perioperative infusion of immunomodulatory
cells, such as transplant-acceptance inducing cells. Afterward, maintenance immunosuppres‐
sion was given for a few months until complete withdrawal, when possible. Overall, although
these trials demonstrated that the infusion of transplant-acceptance inducing cells is feasible,
major concerns remain regarding the efficacy and safety of such an approach. Whether this
approach confers any benefit in the establishment of minimal immunosuppression in renal
transplantation patients when compared with the protocols currently in use is unclear. Lastly,
the optimal dose and timing of cell infusions, along with the most appropriate concomitant
immunosuppression regimen, remains to be determined [55,56].
Patients  who received renal  transplantation after  bone marrow transplantation from the
same donor are also included in this group. Bone marrow transplantation, when success‐
ful, generally results in the total replacement of the recipient’s bone marrow with the do‐
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nor’s  bone  marrow  hematopoietic  cells,  a  condition  referred  to  as  full  chimerism  [57].
Experimental data have confirmed that the infusion of donor-derived bone marrow cells
can prolong allograft survival by still incompletely understood mechanisms [58]. Howev‐
er,  the translation of this model from animals to humans has remained a very challeng‐
ing  task.  In  particular,  an  immunosuppression-free  state  has  been  achieved  only
sporadically  after  living-related  donor  renal  transplantation,  whereas  similar  findings
have  never  been  documented  after  deceased  donor  renal  transplantation  [57,59–63].  In
some studies, the perioperative infusion of donor bone marrow seems to reduce the inci‐
dence  of  acute  and chronic  rejection,  [57,60,61]  and to  improve graft  function when in‐
fused not only systemically but also intrathymically [62,63].
4.1.3. Total lymphoid irradiation protocols
Total lymphoid irradiation was originally developed as a nonmyeloablative treatment for
Hodgkin disease [64].  This  treatment  modality  was first  used about  40 years  ago to in‐
duce prolonged renal allograft survival.  However, total lymphoid irradiation has signifi‐
cant short-  and long-term effects  on lymphocyte subpopulations through suppression of
activated T  cells  and the  IL-2  pathway.  Importantly,  as  the  doses  of  radiation required
for total lymphoid irradiation to be effective are high, with 10 doses of total lymphoid ir‐
radiation (80 to 120 cGy) targeted to the lymph nodes, spleen, and thymus, [54] its clini‐
cal  application  is  limited  by  the  toxicity  that  occurs  with  such  high  doses.  With  the
advent  of  more  effective  immunosuppressive  drugs  and cytolytic  therapy with  antithy‐
mocyte globulin and monoclonal antibodies, the use of total lymphoid irradiation has de‐
clined  considerably  and  is  mainly  applied,  as  stated  earlier,  as  a  nonmyeloablative
preparative regimen of total lymphoid irradiation in combination with the infusion of do‐
nor-derived cells to induce a state of lymphohematopoietic chimerism [65-71].
4.2. Surgical procedures
Currently, Japan has a serious shortage of cadaveric organs. As a result ABO incompatible
living kidney transplantation is being performed [72–76].
Between 2001 and 2004, the ABO-incompatible living kidney transplantation procedure used
a 1-week pretransplant immunosuppression with tacrolimus/mycophenolate mofetil/methyl‐
prednisolon. During this period, splenectomy was performed in all cases and the short–term
outcome was excellent [77]. Graft survival was 93.5% at three years and 91.3% at five years in
these patients [78].
The spleen is involved in the production of B lymphocytes and IgM, so splenectomy can
result  in  decreased  antibody  content  and  increased  tolerance  [79].  This  effect  could  be
considered  analogous  to  the  effect  of  rituximab  (anti-CD20+  monoclonal  antibody),
[80,81]  which prevents acute rejection mediated by antibodies,  resulting in a tolerogenic
effect. Conversely, recent studies show the important role of the spleen for the induction
and maintenance of regulatory CD4+CD25+ T cells, which are important for self-tolerance
[82,83]. This immune regulatory mechanism is known as non-specific suppression of acti‐
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vation and differentiation, and is the result of the release of anti-inflammatory cytokines
[84,85].  Therefore, upon splenectomy, the activity of regulatory T cells is presumably af‐
fected, and this may simulate the mechanisms of action of some currently used immuno‐
suppressant drugs, such as basiliximab and daclizumab (chimeric monoclonal antibodies
that selectively affect T lymphocytes) [86].
5. Conclusion
Despite advances in understanding the cellular and molecular mechanisms of the alloimmune
response, tolerance induction in renal transplantation remains an important clinical challenge.
In clinical practice, prevention of graft rejections has combined tolerance mechanisms, such as
suppression of activated T cells, inhibition the IL-2 pathway, decreased antibody production,
and t chimerism. However, no completely satisfactory results have been achieved. The reason
for these seemingly insurmountable challenges stems from the properties of the alloimmune
response, which are not yet completely understood.
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